SynthesisAddiction (Abingdon, England)2021
The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7).
Synthesis in Addiction (Abingdon, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 248 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Tobacco Use and Incidence of SARS-CoV-2 Infection in the Finnish General Population
The Association Between Tobacco Use and COVID-19 Infection and Adverse Outcomes in Three Nordic Countries: a Pooled Analysis
Tobacco Use and Uptake of COVID-19 Vaccinations in Finland: a General Population Study
Who cites it
248 citing papers in PubMed, 6 syntheses or guidelines pooled it, 392 citations in OpenAlex.
- Prognostic Factors of COVID-19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology.Clinical pharmacology and therapeutics · 2023Pooled it
- Impact of COVID-19 lockdown on smoking and vaping: systematic review and meta-analysis.Public health · 2023Pooled it
- Global prevalence and effect of comorbidities and smoking status on severity and mortality of COVID-19 in association with age and gender: a systematic review, meta-analysis and meta-regression.Scientific reports · 2023Pooled it
- The role of smoking in COVID-19 progression: a comprehensive meta-analysis.European respiratory review : an official journal of the European Respiratory Society · 2023Pooled it
- Smoking is associated with worse outcomes of COVID-19 particularly among younger adults: a systematic review and meta-analysis.BMC public health · 2021Pooled it
- The association of smoking status with SARS-CoV-2 infection, hospitalization and mortality from COVID-19: a living rapid evidence review with Bayesian meta-analyses (version 7).Addiction (Abingdon, England) · 2021Pooled it
- Tobacco smoking and severity of COVID-19: Experience from a hospital-based prospective cohort study in Lyon, France.Journal of medical virology · 2021Trial
- Quit Experiences among Primary Care Patients Enrolled in a Smoking Cessation Pilot RCT Early in the COVID-19 Pandemic.International journal of environmental research and public health · 2021Trial
- Cigarette smoking history, e-cigarette use, and Long COVID: a population-based analysis.Internal and emergency medicine · 2026Article
- Impact of Smoking on Household SARS-CoV-2 Transmission.Healthcare (Basel, Switzerland) · 2026Article
- Cigarette smoking and SARS-CoV-2 infection: multivariable regression and Mendelian randomization analyses in the Norwegian Mother, Father and Child Cohort Study.BMC infectious diseases · 2026Article
- Association Between SARS-CoV-2-Related Experiences and Smoking Cessation in Switzerland: A Repeated Cross-Sectional Study.International journal of environmental research and public health · 2026Article
- Nationwide cross-sectional study results on long-term care and SARS-CoV-2 infection among older adults in Germany during the COVID-19 pandemic.Scientific reports · 2026Article
- COVID-19 outcomes in patients with inflammatory rheumatic diseases: associations with disease subtypes, treatments, and vaccination status.Frontiers in public health · 2026Observational
- Nicotine dependence among critically ill COVID-19 patients: A population-based cohort study.PloS one · 2026Article
- Article
- Seroprevalence and determinants of SARS-CoV-2 anti-nucleocapsid IgG in a vaccinated Iranian adult population: A cross-sectional study, Summer 2023.Human vaccines & immunotherapeutics · 2025Article
- Association between nicotine-dependent patients and delirium in intensive care units: a retrospective cohort study using a large clinical database.BMC psychiatry · 2025Article
- COVID-19 vaccination lowers SARS-CoV-2 infection risk independent of diabetes, cancer and smoking in SHIP-COVID cohort, Northern Germany.Scientific reports · 2025Article
- Seroepidemiology of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Blood Donors from Western Romania, August-September 2023.Microorganisms · 2025Article
188 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
aimsTo estimate the association of smoking status with rates of (i) infection, (ii) hospitalization, (iii) disease severity and (iv) mortality from SARS-CoV-2/COVID-19 disease.
designLiving rapid review of observational and experimental studies with random-effects hierarchical Bayesian meta-analyses. Published articles and pre-prints were identified via MEDLINE and medRxiv.
settingCommunity or hospital, no restrictions on location.
participantsAdults who received a SARS-CoV-2 test or a COVID-19 diagnosis. MEASUREMENTS: Outcomes were SARS-CoV-2 infection, hospitalization, disease severity and mortality stratified by smoking status. Study quality was assessed (i.e. 'good', 'fair' and 'poor').
findingsVersion 7 (searches up to 25 August 2020) included 233 studies with 32 'good' and 'fair' quality studies included in meta-analyses. Fifty-seven studies (24.5%) reported current, former and never smoking status. Recorded smoking prevalence among people with COVID-19 was generally lower than national prevalence. Current compared with never smokers were at reduced risk of SARS-CoV-2 infection [relative risk (RR) = 0.74, 95% credible interval (CrI) = 0.58-0.93, τ = 0.41]. Data for former smokers were inconclusive (RR = 1.05, 95% CrI = 0.95-1.17, τ = 0.17), but favoured there being no important association (21% probability of RR ≥ 1.1). Former compared with never smokers were at somewhat increased risk of hospitalization (RR = 1.20, CrI = 1.03-1.44, τ = 0.17), greater disease severity (RR = 1.52, CrI = 1.13-2.07, τ = 0.29) and mortality (RR = 1.39, 95% CrI = 1.09-1.87, τ = 0.27). Data for current smokers were inconclusive (RR = 1.06, CrI = 0.82-1.35, τ = 0.27; RR = 1.25, CrI = 0.85-1.93, τ = 0.34; RR = 1.22, 95% CrI = 0.78-1.94, τ = 0.49, respectively), but favoured there being no important associations with hospitalization and mortality (35% and 70% probability of RR ≥ 1.1, respectively) and a small but important association with disease severity (79% probability of RR ≥ 1.1).
conclusionsCompared with never smokers, current smokers appear to be at reduced risk of SARS-CoV-2 infection, while former smokers appear to be at increased risk of hospitalization, increased disease severity and mortality from COVID-19. However, it is uncertain whether these associations are causal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.